---
title: "MBX Biosciences posts corporate presentation on precision peptide programs for endocrine, metabolic diseases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295105907.md"
description: "MBX Biosciences released a corporate presentation detailing its precision peptide programs for endocrine and metabolic diseases. Key updates include canvuparatide (MBX 2109) Phase 3 initiation scheduled for Q3 2026, with strong Phase 2 responder rates. The obesity candidate MBX 4291 targets once-monthly dosing, with Phase 1 MAD results expected in Q4 2026. As of June 30, 2026, the company held USD 418.6 million in cash, projecting a runway into 2029."
datetime: "2026-08-06T12:11:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295105907.md)
  - [en](https://longbridge.com/en/news/295105907.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295105907.md)
generator: "portal-rs"
---

# MBX Biosciences posts corporate presentation on precision peptide programs for endocrine, metabolic diseases

-   MBX Biosciences outlined a catalyst schedule led by canvuparatide (MBX 2109) Phase 3 initiation in Q3 2026. \* Canvuparatide Phase 2 Avail responder rates shown at 79% at 12 weeks, 63% at 6 months, 57% at 1 year. \* Phase 3 design calls for N=160, 3:1 randomization, 26-week placebo-controlled period, primary composite responder endpoint at Week 26. \* Obesity candidate MBX 4291 targets once-monthly dosing; 12-week Phase 1 MAD results guided to Q4 2026. \* Cash, cash equivalents, marketable securities totaled USD 418.6 million as of June 30, 2026; runway projected into 2029. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)

## Related News & Research

- [Analyst Maintains Buy on Microbix as China Antigen Sales Normalize and Revenue Growth Recovers](https://longbridge.com/en/news/296018935.md)
- [MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/294163609.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3](https://longbridge.com/en/news/295928409.md)
- [CMI adopts orphan drug field with dedicated center of excellence](https://longbridge.com/en/news/296242891.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**